Story

WuXi AppTec Secures Preliminary Injunction Against U.S. Department of Defense '1260H List' Designation

ENTHMSVIIDZHZH-TWJAKOHI
Aug 9, 20262 min read
WuXi AppTec Secures Preliminary Injunction Against U.S. Department of Defense '1260H List' Designation
Text size
Background

A U.S. federal court has granted a preliminary injunction in favor of WuXi AppTec, temporarily halting the U.S. Department of Defense (DoD) from enforcing its designation of the company on the "1260H list." The ruling provides the pharmaceutical services giant temporary relief as its broader legal challenge against the U.S. government continues.

Court Grants Injunction

The U.S. District Court for the District of Columbia issued the ruling on August 7, 2026, according to a company announcement. The decision prevents the DoD from implementing or taking any action based on the 1260H designation while the underlying lawsuit is litigated. WuXi AppTec stated the ruling shields it from the "immediate adverse effects" of the listing.

The injunction follows a motion filed by the company on June 29, 2026, after it initially sued the DoD on June 11. The court held a hearing on the matter on July 22.

Background on the DoD Designation

WuXi AppTec initiated its lawsuit to challenge what it calls an "erroneous" inclusion on the 1260H list, a roster compiled by the Pentagon of entities it alleges are "Chinese military companies" operating in the United States. While the designation does not impose immediate sanctions, it can carry significant reputational risk and potentially impact future business with U.S. government-related entities.

Sample IUX Markets – In-articleAd

The company stated it took legal action to protect the interests of its shareholders, employees, partners, and clients. In its announcement, WuXi AppTec said it welcomed the court's decision and remains confident that "the facts will prevail after an objective and fair judicial review."

Business Operations Unaffected

WuXi AppTec assured investors and the market that its business operations remain fully normal. The company emphasized that it remains focused on its clients and will continue to provide its services to support patients globally.

The preliminary injunction is a significant development in the ongoing legal dispute, providing the company stability as it seeks to have its name permanently removed from the DoD list through the judicial process.

Read next

More on Stocks
Back to latest news

LATEST